Oxbridge Biotech Roundtable
Oxbridge Biotech Roundtable is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Oxbridge Biotech Roundtable.
Oxbridge Biotech Roundtable is a company.
Key people at Oxbridge Biotech Roundtable.
Oxbridge Biotech Roundtable (OBR) is a non-profit platform founded in 2011 that connects academic innovators with industry professionals to advance life sciences and healthcare ideas.[1][3][4] Its mission centers on fostering conversations between academia and industry, building a global network across the UK and US to translate research into viable ventures.[1][2][5] OBR's investment philosophy emphasizes entrepreneurship through initiatives like the OneStart accelerator, co-founded with SR One in 2012, which supports early-stage healthcare startups via competitions, bootcamps, and mentorship for innovators under 36 with limited funding.[1][2]
OBR impacts the startup ecosystem by bridging transatlantic biotech communities, partnering with organizations like MassBio and corporate VCs such as GlaxoSmithKline's SR One, and running high-profile events like the OneStart Idea Competition, which awarded £100,000 to winners like Puridify Ltd. in 2013.[1][2] With chapters in the UK and US, it catalyzes innovation by providing resources, industry exposure, and support to move academic concepts toward commercialization.[1][3]
OBR emerged in 2011 from a collaborative effort by students at Oxford and Cambridge Universities in the UK, aiming to link academic talent with industry leaders in life sciences.[1][5] Daniel (Dan) Perez, a key founder and later CEO, drove its expansion alongside co-founders, evolving it from a campus-focused discussion forum into a global network with US chapters.[1][2] Early momentum came from partnerships, notably launching the OneStart program in 2012 with SR One, GlaxoSmithKline's venture arm, which drew 100 entries for its inaugural £100,000 competition and selected finalists for pitches to top VCs and pharma executives.[1]
Pivotal moments included semi-finalist bootcamps for business plan development and the 2013 finale at London's Grand Connaught Rooms, where UCL spinout Puridify won and LipoPep took runner-up.[1] By partnering with MassBio around this time, OBR extended its reach to Massachusetts, strengthening UK-US ties and supporting young bio-entrepreneurs.[2]
OBR rides the trend of academia-industry convergence in biotech, where translational research demands strong bridges amid rising demand for disruptive healthcare solutions.[1][2][3] Timing aligns with post-2010s biotech boom, fueled by venture interest in early-stage ideas and global talent mobility between UK hubs like Oxford/Cambridge and US clusters like Boston.[2][5] Market forces favoring OBR include pharma's push for innovation partnering (e.g., Roche, GSK involvement) and accelerators' role in derisking startups amid funding gaps for pre-seed ventures.[1]
It influences the ecosystem by democratizing access—empowering students and early teams via free resources and exposure—while amplifying European bio-entrepreneurship globally, as evidenced by OneStart's worldwide applications.[1][2] This positions OBR as a key enabler in a landscape where 700+ MassBio members and similar networks seek diverse, high-potential ideas.[2]
OBR's influence will likely grow through scaling OneStart and deepening US-UK partnerships, capitalizing on AI-driven drug discovery and personalized medicine trends that demand agile academic-industry links.[1][2] Expect expanded virtual events and corporate tie-ups to sustain momentum, potentially influencing more spinouts amid biotech's projected 2026+ funding resurgence. As a nimble connector rather than a funder, OBR remains uniquely positioned to nurture the next wave of healthcare disruptors, evolving from roundtables to a cornerstone of global bio-entrepreneurship.
Key people at Oxbridge Biotech Roundtable.
